Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Kaplan-Meier Approach

Kaplan-Meier Approach

The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...

Censoring Survival Data

Censoring Survival Data

Survival analysis is a statistical method used to analyze time-to-event data, often employed in fields such as medicine, engineering, and social sciences. One of the key challenges in survival analysis is dealing with incomplete data, a phenomenon known as "censoring." Censoring occurs when the event of interest (such as death, relapse, or system failure) has not occurred for some individuals by the end of the study period or is otherwise unobservable, and it might have many different reasons...

Assumptions of Survival Analysis

Assumptions of Survival Analysis

Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.

Comparing the Survival Analysis of Two or More Groups

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...

Introduction To Survival Analysis

Introduction To Survival Analysis

Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time until a...

Actuarial Approach

Actuarial Approach

The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Bioequivalence Assessment for Intranasal Rapid-Acting Drug Products.

Journal of clinical pharmacology·2026

Same author

Efficacy and safety of 8-week regimens for the treatment of rifampicin-susceptible pulmonary tuberculosis (TRUNCATE-TB): a prespecified exploratory analysis of a multi-arm, multi-stage, open-label, randomised controlled trial.

The Lancet. Infectious diseases·2025

Same author

Enhanced versus standard hydration in acute ischemic stroke: REVIVE-A randomized clinical trial.

International journal of stroke : official journal of the International Stroke Society·2024

Same author

Adjunctive Pascolizumab in Rifampicin-Susceptible Pulmonary Tuberculosis: Proof-of-Concept, Partially-Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial.

The Journal of infectious diseases·2024

Same author

Rosuvastatin adjunctive therapy for rifampicin-susceptible pulmonary tuberculosis: a phase 2b, randomised, open-label, multicentre trial.

The Lancet. Infectious diseases·2023

Same author

Treatment Strategy for Rifampin-Susceptible Tuberculosis.

The New England journal of medicine·2023

Search research articles

Related Experiment Video

Updated: Jun 25, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

Sample size estimation based on event data for a two-stage survival adaptive trial with different durations.

Qingshu Lu¹, Shein Chung Chow, Siu Keung Tse

¹Department of Statistics & Finance, University of Science and Technology of China, Anhui, China.

Journal of Biopharmaceutical Statistics

|February 13, 2009

Summary

This study presents a statistical procedure for combining event data from two clinical trial stages with different durations. It enhances treatment effect evaluation and provides methods for hypothesis testing and sample size calculation in adaptive designs.

More Related Videos

Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index

Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

Measurement of Survival Time in Brachionus Rotifers: Synchronization of Maternal Conditions

Measurement of Survival Time in Brachionus Rotifers: Synchronization of Maternal Conditions

Published on: July 22, 2016

Related Experiment Videos

Last Updated: Jun 25, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index

Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

Measurement of Survival Time in Brachionus Rotifers: Synchronization of Maternal Conditions

Measurement of Survival Time in Brachionus Rotifers: Synchronization of Maternal Conditions

Published on: July 22, 2016

Area of Science:

Clinical Trials Methodology
Biostatistics
Pharmaceutical Research

Background:

Adaptive designs are increasingly used in clinical development to improve efficiency.
Seamless adaptive designs combine dose-finding and confirmatory phases.
Challenges arise when combining data from stages with differing time durations.

Purpose of the Study:

To develop a statistical procedure for combining event data from two clinical trial stages with different time durations.
To address the efficient evaluation of treatment effects in adaptive clinical trials.
To provide methods for hypothesis testing and sample size calculation in such designs.

Main Methods:

Focus on adaptive designs with identical study objectives but varying stage durations.
Development of statistical procedures for merging event data from distinct study periods.
Derivation of results for hypothesis testing and sample size determination.

Main Results:

A statistical procedure for combining event data from two-stage adaptive trials is proposed.
The methodology facilitates efficient treatment effect evaluation.
Results are provided for hypothesis testing and sample size calculations.

Conclusions:

The proposed statistical procedure effectively combines data from adaptive trial stages with different durations.
This approach enhances the efficiency of treatment effect evaluation in clinical development.
The findings support robust hypothesis testing and accurate sample size calculations for comparative treatments.